jpoly4

As Healthy Aging Month arrives, Dr Thomas Rando shares his views on progress in Longevity science. For the past two decades, September has been celebrated as Healthy Aging Month in the United States – an annual period of health observance focused on aging and better health practices.

John Dimos, CEO, Fountain Therapeutics describes their approach to the treatment of age-associated diseases and points out that there is a big difference between chronological and biological age.

To see the affects of aging all you have to do is look in a mirror and watch the changes over time. Fountain Therapeutics is training its artificial intelligence platform to look at individual cells to detect changes that occur as cells get older and discover therapeutics that target underlying mechanisms of aging. 

Fountain is using an unbiased data-driven approach to identify compounds that reverse the biological process of aging, and in contrast to the traditional disease hypothesis-driven approach, the company is agnostic to indication.

As the COVID-19 pandemic continues to usher in an unprecedented era for the global economy and businesses worldwide, Xtalks recently spoke to the CEOs of several companies in the pharmaceutical and biotechnology sectors to learn about how they are navigating the current situation with respect to hiring and recruitment.

Biotechnology startups are seeking to test employees for Covid-19 and taking other precautions to protect laboratory workers as they move to resume more normal operations

We reached out to Fountain’s CEO John Dimos to see what more we can learn about the mysterious San Francisco start-up. When it comes to AI and Longevity drug discovery, there are already several companies out there leveraging the power of machine learning, and we recently covered the $6 million funding injection received by Fountain Therapeutics for …

Fountain’s ‘hypothesis-free’ approach to Longevity AI Read More »

Fountain Therapeutics Inc., a California company working to create treatments for age-related diseases, said Khosla Ventures has led a $6 million series A-1 financing of the startup, with participation from Nan Fung Life Sciences, which earlier contributed $5 million to the round.